Moleculin Biotech (MBRX) News Today → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free MBRX Stock Alerts $4.35 -0.25 (-5.43%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMoleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 21 at 2:14 AMMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLmarkets.businessinsider.com - April 18 at 9:42 AMEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)prnewswire.com - April 18 at 8:30 AMMoleculin Biotech Inc (MBRX)investing.com - April 12 at 12:07 AMMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effectsmarkets.businessinsider.com - April 10 at 12:17 PMMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Propertiesprnewswire.com - April 10 at 8:30 AMMoleculin to Present at the MedInvest Biotech & Pharma Investor Conferencefinance.yahoo.com - March 28 at 11:23 AMMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLfinance.yahoo.com - March 27 at 1:35 PMMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunityprnewswire.com - March 27 at 9:25 AMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 26 at 9:48 AMMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinanznachrichten.de - March 25 at 6:45 PMmarketbeat.com - March 25 at 10:47 AMMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLmarkets.businessinsider.com - March 25 at 9:05 AMMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinance.yahoo.com - March 25 at 9:05 AMMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial Resultsfinanznachrichten.de - March 23 at 10:20 AMMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023investorplace.com - March 22 at 10:03 PMMoleculin Biotech Inc Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:18 PMMoleculin Reports Full Year 2023 Financial Resultsprnewswire.com - March 22 at 4:05 PMmarketbeat.com - March 22 at 6:11 AMMoleculin Biotech announces 1-for-15 reverse stock splitinvesting.com - March 21 at 11:00 PMA Preview Of Moleculin Biotech's Earningsbenzinga.com - March 21 at 5:59 PMMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock Splitfinanznachrichten.de - March 20 at 1:07 PMMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcastprnewswire.com - March 20 at 7:30 AMMoleculin Announces Reverse Stock Splitfinance.yahoo.com - March 19 at 9:29 PMMoleculin to Present at the 36th Annual ROTH Conferencefinance.yahoo.com - March 12 at 9:24 AMHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situationfinance.yahoo.com - February 6 at 3:35 PMMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3finance.yahoo.com - January 24 at 11:33 AMMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Marketfinance.yahoo.com - December 21 at 12:37 AMHC Wainwright & Co. Initiates Coverage of Moleculin Biotech (MBRX) with Buy Recommendationnasdaq.com - December 15 at 1:03 AMBuy Rating for Moleculin Biotech Amid Promising Annamycin Trial Results in AMLmarkets.businessinsider.com - December 14 at 10:02 AMMoleculin Presents Preliminary Efficacy Data Of Annamycin In Acute Myeloid Leukemiamarkets.businessinsider.com - December 11 at 2:54 PMMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meetingfinance.yahoo.com - December 11 at 9:53 AMOppenheimer Keeps Their Buy Rating on Moleculin Biotech (MBRX)markets.businessinsider.com - December 1 at 6:05 PMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 14 at 3:24 PMMoleculin Biotech gains after early data for lead cancer therapymsn.com - November 13 at 6:14 PMMoleculin Biotech, Inc.: Moleculin Reports Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 13 at 1:13 PMMoleculin Biotech Q3 GAAP EPS of -$0.19 beats by $0.03msn.com - November 13 at 1:13 PMMoleculin Biotech Announces Positive Interim Data For Annamycin Trialsmarkets.businessinsider.com - November 13 at 1:13 PMPenny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38%benzinga.com - November 13 at 1:13 PMMoleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Monthsfinance.yahoo.com - November 13 at 1:13 PMMoleculin Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 13 at 8:13 AMMoleculin Biotech Q3 2023 Earnings Previewmsn.com - November 10 at 5:09 PMAnalysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Moleculin Biotech (MBRX)markets.businessinsider.com - November 8 at 8:09 AMMoleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcastfinance.yahoo.com - November 7 at 12:07 PMMoleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastasesfinance.yahoo.com - November 6 at 9:20 AMMoleculin to Participate in the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 11 at 12:46 PMMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)finance.yahoo.com - October 2 at 10:46 AMMoleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)finance.yahoo.com - September 21 at 9:32 AMMoleculin Biotech Reports Independent Report Of No Cardiotoxicity In Annamycinmarkets.businessinsider.com - September 18 at 1:11 PMMoleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycinfinance.yahoo.com - September 18 at 1:11 PM Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry MBRX Media Mentions By Week MBRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.280.44▲Average Medical News Sentiment MBRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼31▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GHSI News Today ELAB News Today ATHE News Today GRTX News Today ERNA News Today AKTX News Today AEZS News Today MNPR News Today AGE News Today NCNA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
